Protocols: CRO industry poised for steady growth as new work in China explodes (in a good way); Vectura dinged on PhIII Flutiform flop
Shares of the UK’s Vectura dropped early Tuesday after the company conceded that Flutiform had failed a Phase III study for COPD. The failed …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
